The Pharmacy Times® Neurology Resource Center is a comprehensive resource for clinical news and expert insights on disorders of the nervous system, including multiple sclerosis, Alzheimer disease, migraine, and Parkinson disease.
August 19th 2025
The complete response letter (CRL) stated that vatiquinone's new drug application (NDA) did not provide substantial evidence of efficacy and would need to be evaluated in a new trial.
Juan Ovalles, MD, PhD, discusses how high placebo response rates driven by background therapy complicate lupus drug trials, and outlines evolving strategies in trial design, clinical practice, and pharmacist-led care to ensure investigational biologics are fairly evaluated and appropriately used in systemic lupus erythematosus.
Read More
An Overview of Vitamins and Supplements in Multiple Sclerosis
By examining the evidence, pharmacists can gain insights into whether these supplements could be integrated into MS treatment regimens to improve patient outcomes.
Read More